Not Yet RecruitingNot Applicable

PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer

China10 participantsStarted 2024-10

Plain-language summary

The objective of this study was to investigate the feasibility of a PD-1 inhibitor in combination with progesterone as a means of preserving fertility in patients with early-stage mismatch repair-deficient (MMRd) endometrial cancer who wish to preserve fertility.

Who can participate

Age range

18 Years – 45 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Be between the ages of 18-45 years old; * Stage IA (FIGO 2009) ; * Confirmed diagnosis of endometrial adenocarcinoma G1-G2 based upon D\&C or hysteroscopy; * Molecular classification of MMRd, determined by immunohistochemical (IHC) for MMR proteins and by the second generation sequencing (NGS) or microsatellite polymerase chain reaction (PCR); * With a strong desire for fertility preservation; * Sign the informed consent. Exclusion Criteria: * Stage IB(FIGO 2009) and above； * Tumour differentiation of G3 or non-endometrioid adenocarcinoma； * Complicated with any other malignancy； * Contraindicated to conservative treatment or the use of pharmaceuticals. * Contraindications to pregnancy, or judged by the researcher to be unfit for pregnancy or delivery.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Complete remission (CR) rate

Timeframe: From start of treatment to trial completion, an average of 3 months

Time to CR

Timeframe: From start of treatment to trial completion, an average of 3 months

Trial details

NCT IDNCT06549855

SponsorPeking University People's Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2029-07

Contact for this trial

Jianliu Wang, Professor

0086-010-88324381 wangjianliu1203@163.com

View on ClinicalTrials.gov More Endometrial Cancer trials